Structured intelligence coverage

Structured records are temporarily unavailable. The published profile and its source ledger remain accessible.

Identity checks do not refresh the age of governance evidence. Open a record for its source date and review state.

Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
33 current organizations shown on this profile
Board positions
33 supported by public sources, 0 supplied by the profile owner
Committee roles
Not establishedNo committee role is currently confirmed by the cited sources
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Served as Chief Executive Officer and Chair of the board; resigned effective February 11, 2025.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Board appointments

Governance

Board appointments, committee responsibilities and disclosed relationships.

Committee appointments across companies · Temporarily unavailable

Structured records for this section are unavailable. This does not establish that no records exist. Published profile sources remain in Evidence & History.

Board and advisory record

Board service

Sources are shown with each role, education record, or credential.

Director

Inhibikase Therapeutics, Inc.

2025-01-01 · current

Confirmed by public sourceView source

Director

Q32 Bio Inc.

2024-01-01 · current

Confirmed by public sourceView source

Director

KALA BIO, Inc.

2015-01-01 · current

Confirmed by public sourceView source

Connections

Explore the roles, education and affiliations published in this record.

Inhibikase Therapeutics, Inc.

Open Inhibikase Therapeutics, Inc. profile →

Director at Inhibikase Therapeutics, Inc.

2025-01-01 → End not stated

current · source reported

Observed: 2026-09-25

Inhibikase Therape…Inhibikase Therapeutics, Inc.KALA BIO, Inc.KALA BIO, Inc.Q32 Bio Inc.Q32 Bio Inc.Mark Iwicki

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec FilingKALA 10-K executive officersSupports AI and ML experience, Cybersecurity experience, Executive company, Executive title, Technology background.Open sourceSource 2 · Sec FilingIKT 10-K executive officersSupports Executive company, Executive title, Other Company Role.Open sourceSource 3 · Sec FilingKALA DEF 14A director slateSupports Board role, Committee assignments.Open sourceSource 4 · Sec FilingIKT DEF 14A director slateSupports Board role, Committee assignments.Open sourceSource 5 · Sec FilingQTTB DEF 14A director slateSupports AI and ML experience, Board role, Committee assignments, Executive company, Executive title, Cybersecurity experience, Technology background.Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:mark-iwicki
Record version
public-0

Published evidence records

11 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. KALA 10-K executive officers

    sec filing · Source published: Apr 15, 2026 · Retrieved: May 16, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Executive company: Executive at KALA BIO, Inc. · Claim reviewed: May 16, 2026
    • Executive title: Executive title: Former Chief Executive Officer · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  2. IKT 10-K executive officers

    sec filing · Source published: Mar 26, 2026 · Retrieved: May 16, 2026

    Supports 3 claims
    • Executive company: Executive at Inhibikase Therapeutics, Inc. · Claim reviewed: May 16, 2026
    • Executive title: Executive title: Chief Executive Officer and Director · Claim reviewed: May 16, 2026
    • Other Company Role: Mark Iwicki is also linked to Q32 Bio Inc. as Chair of the board of directors. · Claim reviewed: May 16, 2026

  3. KALA DEF 14A director slate

    sec filing · Source published: Dec 30, 2025 · Retrieved: May 16, 2026

    Supports 2 claims
    • Board role: Board role: Director · Claim reviewed: May 16, 2026
    • Committee assignments: No committee assignment disclosed in the cited filing · Claim reviewed: May 16, 2026

  4. Open source

    sec proxy · Source published: Dec 30, 2025 · Retrieved: Apr 25, 2026

    Supports 1 claim
    • Professional Role: Director at KALA BIO, Inc. · Claim reviewed: May 16, 2026

  5. IKT DEF 14A director slate

    sec filing · Source published: May 12, 2025 · Retrieved: May 16, 2026

    Supports 2 claims
    • Board role: Board role: Director · Claim reviewed: May 16, 2026
    • Committee assignments: No committee assignment disclosed in the cited filing · Claim reviewed: May 16, 2026

  6. Open source

    sec proxy · Source published: May 12, 2025 · Retrieved: Apr 28, 2026

    Supports 1 claim
    • Professional Role: Director at Inhibikase Therapeutics, Inc. · Claim reviewed: May 16, 2026

  7. QTTB DEF 14A director slate

    sec filing · Source published: Apr 29, 2025 · Retrieved: May 16, 2026

    Supports 7 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Board role: Board role: Chair · Claim reviewed: May 16, 2026
    • Committee assignments: No committee assignment disclosed in the cited filing · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Executive company: Executive at Inhibikase Therapeutics, Inc. · Claim reviewed: May 16, 2026
    • Executive title: Executive title: President and Chief Executive Officer · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  8. Open source

    sec proxy · Source published: Apr 29, 2025 · Retrieved: Apr 28, 2026

    Supports 1 claim
    • Professional Role: Director at Q32 Bio Inc. · Claim reviewed: May 16, 2026

  9. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Inhibikase Therapeutics, Inc. · Claim reviewed: May 16, 2026

  10. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Q32 Bio Inc. · Claim reviewed: May 16, 2026

  11. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of KALA BIO, Inc. · Claim reviewed: May 16, 2026

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · CorroboratedAI and ML experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Board membership · Source reportedServes on the board of Inhibikase Therapeutics, Inc.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board membership · Source reportedServes on the board of KALA BIO, Inc.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board membership · Source reportedServes on the board of Q32 Bio Inc.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board role · Source reportedBoard role: Chair1 source
Verification
Source reported
Confidence
92%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Board role · CorroboratedBoard role: DirectorSupported by 2 public records2 sources
Verification
Corroborated
Confidence
92%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Committee assignments · CorroboratedNo committee assignment disclosed in the cited filingSupported by 3 public records3 sources
Verification
Corroborated
Confidence
88%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Cybersecurity experience · CorroboratedCybersecurity experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive company · CorroboratedExecutive at Inhibikase Therapeutics, Inc.Supported by 2 public records2 sources
Verification
Corroborated
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive company · Source reportedExecutive at KALA BIO, Inc.1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive title · Source reportedExecutive title: Chief Executive Officer and Director1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive title · Source reportedExecutive title: Former Chief Executive Officer1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive title · Source reportedExecutive title: President and Chief Executive Officer1 source
Verification
Source reported
Confidence
85%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Other Company Role · Source reportedMark Iwicki is also linked to Q32 Bio Inc. as Chair of the board of directors.1 source
Verification
Source reported
Confidence
70%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Technology background · CorroboratedTechnology background: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

View all sources11 records
  1. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: AI and ML experience · Cybersecurity experience · Executive company · Executive title · Technology background

  2. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: Executive company · Executive title · Other Company Role

  3. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: Board role · Committee assignments

  4. https://www.sec.gov/Archives/edgar/data/1479419/000182912625010356/kalabio_def14a.htm

    Sec Proxy · Tier not stated · Reviewed Apr 25, 2026

    Supports: Director at KALA BIO, Inc. (NASDAQ: KALA)

  5. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: Board role · Committee assignments

  6. https://www.sec.gov/Archives/edgar/data/1750149/000095017025069152/ikt-proxy-def-annual-jun.htm

    Sec Proxy · Tier not stated · Reviewed Apr 28, 2026

    Supports: Director at Inhibikase Therapeutics, Inc. (NASDAQ: IKT)

  7. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: AI and ML experience · Board role · Committee assignments · Executive company · Executive title · Cybersecurity experience · Technology background

  8. https://www.sec.gov/Archives/edgar/data/1661998/000095017025059558/qttb-20250429.htm

    Sec Proxy · Tier not stated · Reviewed Apr 28, 2026

    Supports: Director at Q32 Bio Inc. (NASDAQ: QTTB)

  9. https://www.sec.gov/Archives/edgar/data/1750149/000095017025069152/ikt-proxy-def-annual-jun.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership

  10. https://www.sec.gov/Archives/edgar/data/1661998/000095017025059558/qttb-20250429.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership

  11. https://www.sec.gov/Archives/edgar/data/1479419/000182912625010356/kalabio_def14a.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership